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Background: Previous reviews (2005 to 2009) on preterm infants given probiotics or prebiotics with breast milk or
mixed feeds focused on prevention of Necrotizing Enterocolitis, sepsis and diarrhea. This review assessed if
probiotics, prebiotics led to improved growth and clinical outcomes in formula fed preterm infants.
Methods: Cochrane methodology was followed using randomized controlled trials (RCTs) which compared preterm
formula containing probiotic(s) or prebiotic(s) to conventional preterm formula in preterm infants. The mean
difference (MD) and corresponding 95% confidence intervals (CI) were reported for continuous outcomes, risk ratio
(RR) and corresponding 95% CI for dichotomous outcomes. Heterogeneity was assessed by visual inspection of
forest plots and a chi2 test. An I2 test assessed inconsistencies across studies. I2> 50% represented substantial
heterogeneity.
Results: Four probiotics studies (N=212), 4 prebiotics studies (N=126) were included. Probiotics: There were no
significant differences in weight gain (MD 1.96, 95% CI: -2.64 to 6.56, 2 studies, n=34) or in maximal enteral feed
(MD 35.20, 95% CI: -7.61 to 78.02, 2 studies, n=34), number of stools per day increased significantly in probiotic
group (MD 1.60, 95% CI: 1.20 to 2.00, 1 study, n=20). Prebiotics: Galacto-oligosaccharide / Fructo-oligosaccharide
(GOS/FOS) yielded no significant difference in weight gain (MD 0.04, 95% CI: -2.65 to 2.73, 2 studies, n=50),
GOS/FOS yielded no significant differences in length gain (MD 0.01, 95% CI: -0.03 to 0.04, 2 studies, n=50). There
were no significant differences in head growth (MD −0.01, 95% CI: -0.02 to 0.00, 2 studies, n=76) or age at full
enteral feed (MD −0.79, 95% CI: -2.20 to 0.61, 2 studies, n=86). Stool frequency increased significantly in prebiotic
group (MD 0.80, 95% CI: 0.48 to 1.1, 2 studies, n=86). GOS/FOS and FOS yielded higher bifidobacteria counts in
prebiotics group (MD 2.10, 95% CI: 0.96 to 3.24, n=27) and (MD 0.48, 95% CI: 0.28 to 0.68, n=56).
Conclusions: There is not enough evidence to state that supplementation with probiotics or prebiotics results in
improved growth and clinical outcomes in exclusively formula fed preterm infants.
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Growth is a major challenge for premature and low birth
weight infants (born < 37 weeks gestation or with a birth
weight of < 2500 g). They have several factors that put
them at risk for nutritional deficiencies resulting in poor
growth. Decreased nutrient stores result in low body
stores of glycogen, fat, protein, fat soluble vitamins, cal-
cium, phosphorus, magnesium and trace minerals.* Correspondence: nkmugambi@hotmail.com
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reproduction in any medium, provided the orPreterm infants require increased energy and nutrients
for rapid growth and may need a 10 fold increase in
weight gain in order to achieve optimum catch up
growth [1,2]. To achieve optimum growth for the pre-
term infant, the goals are to continue the process of
intra-uterine growth in an extra-uterine environment
until 40 weeks post conception, foster catch-up growth
and nutrient accumulation in the post discharge period
[3-6]. A weight gain of 15 to 20 g/ kg/day, length of 0.75
to 1.0 cm/week and head circumference 0.75 cm/week is
required. This is difficult to achieve and requires be-
tween 130 – 135 kcal / kg /day to maintain this growthral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.nutritionj.com/content/11/1/58rate [3]. Furthermore, infants lose weight after birth (up
to 6% to 8% for extreme low birth weight infants) and
they often do not regain the weight for up to 1 to 2
weeks [5]. Daily growth monitoring (weight gain, linear
and head circumference) then becomes vital.
Preterm infants have immature physiological systems
due to an underdeveloped gastrointestinal barrier func-
tion as reflected by increased intestinal permeability. As
a result, potentially pathogenic bacteria translocate from
the intestinal lumen and cause systemic infections [7].
Reducing intestinal permeability is associated with gut
maturation which promotes growth and avoids severe
infections [4]. In addition, digestive and absorptive cap-
abilities are decreased due to low concentration of lac-
tase, pancreatic lipase and bile salts. Gastrointestinal
motility and stomach capacity are decreased which limits
feeding volume and gastric emptying. A coordinated
suck and swallow is not developed until 32 to 34 weeks
gestation. Introduction of enteral feeding maybe delayed
due to increased risk of aspiration [1,2,8,9]. Preterm
infants in neonatal intensive care units (NICUs) develop
a different intestinal microbiota compared to healthy
breast fed infants. This is due to decreased exposure to
the maternal microbiota, increased exposure to organ-
isms that colonize NICUs, multiple courses of antibiotics
and delays in feeding [8,9].
Humans have consumed probiotics in the form of fer-
mented food, dairy products and more recently infant
and toddler formula. Probiotics are defined as “live
microorganisms” which when administered in adequate
amounts confer a health benefit to the host [10]. The
main probiotic organisms used worldwide belong to the
genera Lactobacillus and Bifidobacteria and are found in
the gastrointestinal micro flora [10,11]. Prebiotics are
found in fruit and vegetable components, they are non-
digestible food ingredients that benefit the host by se-
lectively stimulating the growth and/or activity of one or
a limited number of bacteria in the colon and improving
the host’s health [12,13]. The most widely studied pre-
biotics are inulin, fructo-oligosaccharide (FOS) and
galacto-oligosaccharide (GOS) which are plant storage
carbohydrates in vegetables, cereals and fruit. FOS and
inulin are added to different foods as fat and sugar repla-
cements to improve texture or for their functional bene-
fits [12,14-16]. Probiotics and prebiotics are added to
infant formula to promote an intestinal microbiota re-
sembling that of breastfed infants which have a greater
concentration of bifidobacteria and less pathogenic bac-
teria than formula fed infants [10,17].
There are a number of ways in which probiotics im-
prove health. Health benefits conferred by probiotic bac-
teria are strain specific and not species or genus specific
[10]. Probiotic bacteria improve health by affecting the
immune system in different ways. They increasecytokine production such as Interleukin-6 (IL-6),
Interferon- gamma (IFN-γ), Tissue Necrosis Factor –
alpha (TNF-α), Interleukin-1beta (IL-1β) and
Interleukin-10 (IL-10) [18]. Some strains increase phago-
cytic activity of peripheral blood leukocytes (monocytes,
polymorphonuclear cells). Other strains strengthen the
mucosal barrier function by promoting the production
of mucosal antibodies and reducing the trans mucosal
transfer of antigens. This reduces the intestinal perme-
ability which in turn promotes growth [19-22]. Probio-
tics bacteria also enhance production of low molecular
weight antibacterial substances produced by epithelial
cells and production of short chain fatty acids, the main
energy source for colonocytes. This maintains the integ-
rity of colon mucosa [19,23-26].
Prebiotics are resistant to digestive enzymes and pH
extremes found in the human gastrointestinal tract.
They transit through the upper gastrointestinal tract and
reach the colon intact where they are selectively fermen-
ted by indigenous bacteria, especially bifidobacteria and
lactobacilli [12,15,26,27]. Beneficial bacteria (including
bifidobacteria and lactobacilli) possess enzymes needed
to metabolize prebiotics, while other bacteria (such as E
coli, clostridia and salmonella) do not [15,27]. Consump-
tion of prebiotics by preterm formula fed infants results
in an increase of beneficial microorganisms in the colon,
decreasing harmful bacteria to the levels found in breast-
fed infants. This improves the gastrointestinal mucosal
barrier (decreasing intestinal permeability) which pre-
vents infections and eventually results in improved
growth [27,28]. In general the aim of adding probiotics
and prebiotics to preterm infant formula is to improve
growth, development and decrease infections by promot-
ing an intestinal microbiota resembling that of breastfed
infants [9,29,30].
The effects of probiotics on the intestinal microbiota
of premature infants have been varied due to differences
on gestational age and products administered. Effects of
probiotics on weight gain have also been varied. Admin-
istration of Bifidobacteria breve led to improved weight
gain while Saccharomyces bourladii did not [9]. With
premature infants optimal strains and dose regimens are
yet to be examined closely [8]. The effects of prebiotics
on the growth of premature infants are not clear. If pre-
biotic supplementation reduces the risk of Necrotizing
Enterocolitis (NEC) or improves feed tolerance in very
low birth weight infants is yet to be established [8,9]. Re-
cent systematic reviews (published from 2005 to 2009)
on the use of probiotics or prebiotics in preterm infants
have focused on prevention of NEC and / or sepsis, im-
pact on diarrhea [31-34]. These reviews focused on stud-
ies that used breast milk and mixed feeds (formula
combined with breast milk). This review included infants
given only infant formula and focused on growth with
Table 1 Search strategy used in PUBMED
1) Search (probiotic* OR prebiotic*) AND (infant formula* OR infant
feeding OR formula OR formula milk) AND (preterm or premature
or low birth weight babies) AND (randomized controlled trial*
OR controlled clinical trial* OR random allocation*) Limits: Human
2) Search (probiotic* infant formula* OR prebiotic* infant formula*
OR prebiotic* OR probiotic*) AND (infant formula* OR infant
feeding) AND (premature OR preterm) AND (randomized controlled
trial* OR controlled clinical trial OR random allocation* OR
double blind method OR single-blind method OR clinical trial
OR placebo* OR random* OR research design OR comparative
study OR follow-up studies OR prospectiv* OR volunteer* OR
control* (singl* OR doubl* OR trebl* OR tripl*) NEAR (blind*
OR mask*) Limits: Human
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previous reviews.
The Human Research Ethics Committee at the Univer-
sity of Stellenbosch, South Africa reviewed the review
protocol (unpublished), ruled that all data to be col-
lected for this review was from the public domain and
was therefore exempt from ethical approval.
Objective
To assess if addition of probiotics or prebiotics to pre-
term infant formula led to improved growth and clinical
outcomes in preterm or low birth weight infants.
Methods
Eligibility criteria
All randomized controlled trials (RCTs), irrespective of
language, which compared the use of preterm infant for-
mula containing probiotic(s) or prebiotic(s) to conven-
tional preterm infant formula without or with placebo
amongst preterm infants born <37 weeks gestation, low
birth weight infants with <2.5 kg at birth and hospita-
lized, receiving formula feeds and / or parenteral feed
were considered. Studies published as abstracts were
included if sufficient information could be obtained to
assess study quality and obtain relevant study findings.
Outcome measurements
Primary outcomes included: Short term growth para-
meters (assessed for entire study duration approximately
4 weeks): weight gain (grams/day or grams/week), linear
growth (centimeters/week), head growth (cm/week). Sec-
ondary outcomes included: Complications: Incidence of
NEC (defined as suspected or confirmed positive Bell
stage II or more), Sepsis (defined as signs or symptoms
of infection and positive blood culture), Other infections
(example bacteraemia defined as blood cultured positive
for bacteria), Mortality / death. Adverse events during
entire study duration: Number of days on parenteral,
number of days to full enteral nutrition, maximal enteral
feed (millilitres/day, millilitres/kilogram/day, millilitres
/kilogram). Feed intolerance: Incidence of vomiting, gas-
tric aspirates, abdominal distension. Stool characteristics:
Stooling frequency and stool consistency as firm, loose
or watery. Changes in intestinal permeability as mea-
sured by ratio of Lactulose / mannitol in urine or other
sugar absorption tests (such as lactulose / L – rhamnose
ratio, D- xylose, 3-O2- methyl-D- glucose tests). Gastro-
intestinal (GI) micro flora: number of colony forming
units (cfu) of bifidobacteria, lactobacillus and pathogens
post intervention).
Search method for identification of studies
A literature search in all languages was conducted on
electronic databases which included The CochraneCentral Register for Controlled Trials 2009, Scopus
(1990 to 19/01/2010), EBSCO host (1960 to 15/11/
2009), OVID (1950 to 01/12/2009), SPORT Discus (1960
to 19/01/2010), Web of Science (1970 to 19/01/2010),
Science Direct (1950 to 30/11/2009), EMBASE (1980 to
01/12/2009), CINAHL (1981 to 19/01/2010), PUBMED /
MEDLINE (1966 to 10/04/2010), Latin American Carib-
bean Health Sciences literature (LILACS), (1965 to 19/
01/2010), NLM Gateway (1950–1966). RCTs published
in non-English language journals were translated by in-
dependent translators who were familiar with the subject
matter. The search strategy used to search PUBMED is
shown on Table 1. This search strategy was modified to
search other electronic databases.
We conducted a hand search on abstracts of major
conference proceedings such as the Pediatric Academic
Society meetings (www.pas-meetings.org, www.abstracts2-
view.com), cross checked references cited in RCTs and in
recent reviews (published from 2005 to 2009) for additional
studies not identified by electronic searches and specialty
journals which were not included in any database such as
Pediatrika, Chinese Journal of Microecology and Inter-
national Journal of Probiotics and Prebiotics.
To identify on-going and unpublished trials, we con-
tacted experts in the field, manufacturers of infant for-
mula containing probiotics and prebiotics, we searched
web sites of companies that have conducted or were
conducting RCTs on probiotics and prebiotics e.g.
Pfizer (www.pfizerpro.com/clinicaltrials), Chris Hansen
Laboratory (www.chr-hansen.com/research_development/
documentation.html). We also searched prospective trial
registries such as World Health Organisation (WHO)
International Clinical Trials Registry Platform Search Por-
tal (www.who.int/trialsearch), Clinical Trials.gov register
(www.clinicaltrials.gov), Current Controlled Trials meta
Register of Controlled Trials [mRCT] (www.controlled-
trials.com/mrct) and www.clinicaltrialresults.org.Selection of studies
Two reviewers (MM, ML) independently reviewed all
abstracts, citations and identified potentially eligible
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by one reviewer (MM) and the pre-specified selection
criteria applied independently by two reviewers (MM,
ML) using a study eligibility form. (Figure 1) If more
than one publication of a study existed, all reports of theReview title:
Study ID (Author last name, initials)
Refworks ID number
Date of review for eligibility (DD-MM-YYYY)
Journal title
Title of study/article
Year/volume/issue/page
Extractor (Last name, initials)
Type of study
Is this study a Randomized controlled study? YES
YES
YES
YES
YES
YES
Trial intervention
Preterm infant formula containing probiotic(s)
Preterm infant formula containing prebiotic(s)
Conventional preterm formula / placebo
Study Participants
Premature infants <37 weeks gestation
Low birth weight infants < 2.5 kg at birth
Study Outcomes ( >1 outcomes below)
Short term growth parameters (Wt,Ht,HdCircum)
Adverse events (# days on parenteral, full enteral 
nutrition, maximal enteral feed, vomiting, GI aspirates, 
abdomen distension, stool characteristics- consistency, 
frequency)
Complications (NEC, Sepsis, other infection, death)
Intestinal permeability
Other reasons for excluding study NO
IncludeFinal decision
GI Microflora (Bifidobacteria, Lactobacillus, pathogen cfu)
Go to
Put a 
Comments
STUDY ELIGIBIL
Probiotic, p
Go to
Go to
YES
YES
YES
YES
Figure 1 Study eligibility form.study were grouped together under one study name.
Any disagreements between the reviewers were resolved
through discussion. If disagreements could not be
resolved a third party was consulted. Trial authors were
contacted if eligibility was unclear.UNCLEAR NO
UNCLEAR NO
UNCLEAR NO
UNCLEAR NO
UNCLEAR NO
UNCLEAR NO
Exclude
Exclude
Exclude
Yes
ExcludeUnclear
For 
discussion
 next question
check (√ ) mark in appropriate box.
ITY FORM
rebiotics infant formula use in preterm or low birth 
weight infants: A systematic review
Clarify missing information
 next question
 next question
UNCLEAR NO
UNCLEAR NO
UNCLEAR NO
UNCLEAR NO
Figure 2 Process followed in the selection of studies.
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Two reviewers (MM, ML) independently assessed the
risk of bias of included studies as described in the
Cochrane Handbook for Systematic Reviews for Inter-
ventions according to the following 6 components. 1) se-
quence generation; 2) allocation concealment; 3)
blinding; 4) incomplete outcome data; 5) selective out-
come reporting; and 6) other sources of bias [35]. Where
necessary, trial authors were contacted for clarification
on the methodology of their studies. Any disagreements
regarding risk of bias were resolved through discussion
between MM, ML and RB.
Data extraction and management
Two reviewers (MM, ML) independently extracted data
using a pre tested data extraction form. The reviewers
(MM, ML) cross checked data and resolved any differ-
ences through discussion. One reviewer (MM) entered
the data in Review Manager (RevMan 5) and the other
reviewer (ML) validated the data. Trial authors were
contacted for missing data or for clarification.
Data synthesis and management
Results for probiotic and prebiotic studies were analysed
separately. For continuous outcomes the mean differ-
ence (MD) and corresponding 95% confidence intervals
(CI) were calculated. For dichotomous outcomes, the
risk ratio (RR) and corresponding 95% CI were calcu-
lated. Trial authors were contacted if there was missing
data in their reports. Available case analysis was used
where there was missing data. The potential impact of
the missing data on the results of the review is addressed
in the discussion section. Heterogeneity of the trials used
in the review was assessed by visually inspecting the for-
est plots to detect overlapping confidence intervals and
by performing a chi2 test. A p<0.1 was considered statis-
tically significant. An I-square test (I2) was used to test
for inconsistencies across studies. If the I2 exceeded 50%
and visual inspection of the forest plot supported these
results, this represented substantial heterogeneity.
If the included studies were not clinically diverse and
had similar outcome measures, a Meta - analysis was
carried out in Review Manager software (RevMan 5) by
one review author (AM). For continuous data, if hetero-
geneity was low, an inverse variance fixed-effect method
was used. If heterogeneity was high, an inverse variance
random-effects method was used. For dichotomous data,
if heterogeneity was low, a Mantel-Haenszel fixed-effects
method was used. If heterogeneity was high, a Mantel-
Haenszel random-effects method was used. The source
of heterogeneity was explored through subgroup analysis
with respect to the type of intervention. If studies were
too diverse, no Meta-analysis was conducted and a nar-
rative synthesis was provided. We had intended toperform sensitivity analysis with respect to study quality
in order to investigate the robustness of our findings but
this could not be done mainly because most of the
meta-analysis had too few studies (mostly two) to war-
rant sensitivity analysis. In some cases, all the studies in
the meta-analysis had similar study quality thus render-
ing sensitivity analysis inappropriate.
Results
Results of the search and description of studies
Electronic search of available databases yielded 151 cita-
tions. After reading titles, abstracts, the duplicate reports
were removed and 35 potentially relevant articles were
identified. A hand search yielded 4 more articles. The
full text reports were retrieved and reviewed for eligibil-
ity. One study was published in two other reports. The
three studies were considered as one study since they
reported the same identical study and are referred to as
Boehm 2002 in this review [36-38]. Eight published
Table 2 Excluded studies with reasons for exclusion
Reasons for exclusion of studies
Use of breast milk or mixed feeds
(breast milk and formula)
No use of
probiotic,
prebiotic
Follow up -
study,
Not RCT
Duplicate
publishing
Different
inclusion criteria
and outcomes
Type of feed
unspecified
Agarwal 2003 [52] Lin H-C 2008 [53] Riskin 2009 [54] Andrews 1969 [55] Chou I-C 2009 [56] Stansbridge
1993 [57]
Cukrowska
2002 [58]
Karvonen
2002 [51]
Bin-Nun 2005 [59] Manzoni 2006 [60] Rouge 2009 [61] Taylor 2009 [62] Hoyos 1999 [63] Wang 2007 [64]
Dani 2002 [65] Millar 1993 [66] Samanta 2005 [67] Lidesteri 2003 [68]
Kitajima 1997 [69] Mohan 2006 [70] Westerbeek 2008 [71]
Lee 2007 [72] Mohan 2008 [73] Westerbeek 2010 [74]
Lin H-C 2005 [75] Patole 2005 [76] Yong Gu 2009 [77]
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[36,39-45] and five on-going studies were included in
this review [46-51]. The process followed is shown in
Figure 2. Table 2 gives a list of 27 studies which wereTable 3 A summary of four included probiotic studies
Costalos 2003 [39] Indrio 2008 [42]
Location of study Athens, Greece University of Bari,
Policinico, Italy
Participants -
inclusion criteria
28 - 32 weeks gestation 3- 5 days old, appr
for gestational age
preterm infants wi
normal agpar scor
Number of study
participants
Study group=51 ,
Placebo = 36
Study group = 10
Placebo = 10
Probiotic bacteria used Saccharomyces Bourlardii Lactobacillus Reute
ATCC 55730
Dose of probiotic 109cfu at 50mg/kg
every 12 hours
1 X 108cfu/day
Placebo Maltodextrin Indistinguishable
placebo
Dose of placebo 50 mg /kg / 12 hours Not reported
Treatment initiation 1st week of life as soon as
enteral feed was tolerated
At 3–5 days of life
Treatment duration 30 days 30 days
Reported Outcomes
Growth parameters Weight gain Weight gain
Timing and duration of
measurement of
growth parameters
Measured daily
for 30 days
Measured daily
for 30 days
Feed tolerance Number of days to
full enteral feed,
Maximal enteral
feed, vomiting
Number of days to
full enteral feed,
Maximal enteral
feed, vomiting
Stool characteristics Stooling frequency
Complications NEC, Sepsis
Intestinal permeability Changes in Intestinal
permeability
Changes in
gastrointestinal microflora
cfu of bifidobacteria,
lactobacillus, pathogensexcluded for: use of breast milk or mixed feeds (18 stud-
ies), no use of probiotic or prebiotic (2 studies), being a
follow –up study, not RCT (3 studies), duplicate publish-
ing (1 study); using different inclusion criteria withReuman 1986 [41] Stratiki 2007 [40]
Gainesville, Florida, USA Alexandra Regional
Hospital, Greece
opriate
,
th
es
Premature infants,
<2000g at birth,
less than 72 hours old
(>24 old to <72 hours old)
27 to 37 weeks gestation,
in stable state
, Study group = 15,
Placebo = 15
Study group = 41,
Placebo = 34
ri Lactobacillus acidophilus Bifidobacteriumlactis
9 X 106cfu/ml formula 2 X 107cfu/g milk powder
Conventional
preterm formula
Conventional
preterm formula
1st 72 hours of life 1st 2 days of life
Not specified 30 days
Weight gain Weight gain, Linear growth,
Head circumference
Measured daily,
duration not specified
Weight gain: measured daily,
Lineargrowth (measured weekly),
Head circumference
(measured weekly)
Maximal enteral feed Number of days to
full enteral feed,
Maximal enteral feed
Mortality / death NEC, Sepsis
Changes in Intestinal
permeability
cfu of bifidobacteria
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specified (1 study). No eligible studies were excluded for
failure to report the review’s pre-specified outcomes.
A summary of the included probiotic, prebiotic and
on-going studies are shown in Tables 3, 4 and 5. The
included probiotic studies (N=212) were conducted in
Greece, Italy and United States of America (USA).
Treatment duration was 30 days using different probio-
tics. All four probiotic studies reported short term
growth parameters (weight gain) which were recorded
daily during the entire study duration [Table 3]. None of
the probiotic studies reported data on: other types of
infections, use of parenteral nutrition, feed intolerance
(gastric aspirate [ml], abdominal distension) and stool
consistency. The included prebiotic studies (N=126)
were conducted in conducted in Greece, Italy, and Ger-
many. Treatment duration ranged from 14 days to 28
days. All four prebiotic studies reported short term
growth parameters (weight gain, length, head growth)
which were recorded at different intervals during the en-
tire study duration [Table 4]. None of the prebiotic stud-
ies reported data on: complications (NEC, sepsis, other
types of infections, death / mortality), use of parenteral
nutrition, feed intolerance (vomiting, gastric aspirateTable 4 A summary of four included prebiotic studies
Boehm 2002 [36] Indrio 2009
Location of study Milan, Italy University o
Policinico, It
Participants - entry criteria <32 weeks gestation Healthy pre
Number of study participants Study group = 15,
Placebo = 15
Study group
Placebo = 1
Prebiotic used GOS 90%, FOS 10% scGOS, lcFO
Dose of prebiotic 1g/dl 0.8 g/dl
Placebo Maltodextrin Maltodextri
Dose of placebo 1 g/dl 0.8 g/dl
Treatment initiation When enteral feed ≥
80 mls /kg/day was tolerated
Not clear
Treatment duration 28 days 15 days
Reported Outcomes
Growth parameters Weight gain, linear growth Weight gain
head growt
Timing and duration of
measurement of
growth parameters
Measured on days 1, 7, 14, 28 Measured b
study, days
Feed tolerance Number of days to full enteral
feed, maximal enteral feed
Number of
full enteral
maximal en
Stool characteristics Stooling frequency,
consistency
Changes in gastrointestinal
microflora
cfu bifidobacteria[ml], abdominal distension) and changes in intestinal
permeability.
Risk of bias
The quality of the included studies was assessed across
six domains using guidelines from the Cochrane Hand-
book for Systematic Reviews of Interventions [35]
(Figure 3).
Random sequence generation: Three trials described
clearly the methods used for random sequence gener-
ation [40,41,44]. Mihatsch used computer generated ran-
dom lists with variable block sizes [44]. Stratiki used
balance block randomization using random numbers
[40] and Reuman used random numbers list combined
with the last digit of the patients’ medical record [41].
The method used for random sequence generation was
not clearly described 5 studies [36,39,42,43,45].
Allocation Concealment: In two trials treatment allo-
cation was adequately concealed [33,40]. In the Stratiki
trial, treatment allocation was conducted by a third party
who was not involved in the study (Nutritional service)
[40]. Mihatsch used precoded sachets in sealed envel-
opes [44]. In one study treatment allocation was not ad-
equately concealed because the method used was[43] Kapiki 2007 [45] Mihatsch 2006 [44]
f Bari,
aly
Athens, Greece Ulm University, Germany
term newborns ≤ 36 weeks gestation < 1500 g birth weight
= 10 ,
0
Study group = 36,
Placebo = 20
Study group = 10,
Placebo = 10
S at ratio 9:1 FOS GOS, FOS
0.4g/100ml 1g/dl
n Maltodextrin Maltodextrin
0.4 g 1.8 / 90 ml
Exclusively formula
fed at start of study
At full enteral feed at
start of study
14 days 15 days
, linear growth,
h
Weight gain, linear growth,
head growth
Weight gain
efore start of
3, 5, 15
Measured on days 1, 7, 14 Weight gain: reported as
“Average weight
gain during study.”
days to
feed,
teral feed
Number of days to
full enteral feed
Number of days to
full enteral feed,
maximal enteral feed
Stooling frequency,
consistency
Stool viscosity,
Stooling frequency,
consistency
cfu bifidobacteria,
pathogens
Table 5 A summary of five on-going studies
Jacobs 2007 [46] Lozano 2008 [47] Al-Hosni 2010 [48] Patole 2009 [49] Underwood 2009 [50]
Location of study Australia Colombia USA Australia USA
Participants -
inclusion
criteria
<32 weeks gestation,
<1500 g birth weight,
1–3 days old
Birth weight
<2000 grams,
< 48 hours of age,
admission in NICU,
Hemodynamic-ally
stable
Extremely Low Birth
weight infants:
< 1000 grams,
1 to 14 old,
intention to s
tart enteral feeds
32 weeks Gestation
and 6 days,
<1500g birth weight,
ready to commence
on enteral feeds
for up to 12 hours
< 500grams birth weight,
age less than 33 weeks
gestation, exclusively
formula fed
Probiotic
bacteria used
Bifidobacteriuminfantis,
BifidobacteriumBifidus,
Streptococcus
thermophilus
Lactobacillus reuteri
DSM 17938
Lactobacillus rhamnosus
GG, Bifidobacteriuminfantis
Lactobacillus acidophilus
375 million,
bifidobacteriumbifidum,
bifidobacteria longus
1. ProlactPlus
2. GOS
3. Bifidobacteriuminfantis
4. Bifidobacteriumanimalis
Dose 1X109 1X108 CFU in 5
drops of oil
suspension
1/ day until
discharge.
L rhamnosus:
500 million cfu,
B.infantis:
500 million cfu
L. acidophilus:375 m
organisms, B bifidum,
B. longus:
125 million organisms
1. week 1 95:5
to week 5 75:25
2. week: 0.25g/dL,
to week 5: 2.0 g/dL
3. week 1: 5X107,
to week 5: 4.2 X109
4. week 1: 5X107,
to week 5: 4.2 X109
Start date of
study
July- 2007 August 2008 February 2008 June 2009 June 2009
Reported
Outcomes
Sepsis, Sepsis Average weight gain Sepsis Fecal microflora
NEC NEC Growth velocity NEC
Death Death Feed tolerance All-cause mortality
Frequency of events Volume of feed/day Time to reach full feeds
(150 mls/kg/day)
Length of
hospital admission
Gut colonisation
by probiotic
Number of
antibiotic courses
Days to f
ull enteral feeds
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http://www.nutritionj.com/content/11/1/58alternation, matching of infants by birth weight and ges-
tational age [41]. In the rest of the studies, allocation
concealment was not clearly demonstrated or described
[36,39,42,43].
Blinding: Blinding of study participants, care providers
and assessors was clearly done in 4 trials [39-41,44]. In
the other 4 trials, there was not enough information
given on the blinding method to make a judgement
[36,42,43,45].
Incomplete outcome data: Reported outcome data was
satisfactory for all the eight included studies. Five studies
had no missing outcome data [36,41-44]. In other three
studies, the missing outcome data was balanced across
the intervention groups with similar reasons reported
[39,40,45].
Selective reporting (reporting bias): In all eight studies,
the pre-specified outcomes in the methods section were
reported in the results section [36,39-45].Other potential sources of bias: Only one trial had a
baseline imbalance which was a potential source of bias.
Costalos had 51 infants enrolled in the treatment group
and 36 infants in the placebo group. No explanation was
presented whether the imbalance was due to a problem
at randomization stage [39]. All other studies appeared
to be free from other potential sources of bias.
Effects of interventions
Probiotics versus control
Four studies investigated the effect of probiotic adminis-
tration versus no probiotic (control group) [39-42].
Primary outcomes: short term growth parameters
Weight gain All four studies reported on weight gain
[39-42]. Results from two studies (n=34) were pooled in
a meta-analysis [41,42]. There was no statistically
Low risk of bias 
Unclear risk of bias 
High risk of bias 
Figure 3 Methodological quality of included studies.
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http://www.nutritionj.com/content/11/1/58significant difference in weight gain (g/day) between the
probiotic and control groups (MD 1.96, 95% CI: -2.64 to
6.56). No statistically significant heterogeneity was
observed (Chi2=0.18, p=0.67, I2=0%) (Figure 4)Figure 4 Effect of probiotic administration on weight gain (g/day).Two studies [39,40] reported their results using med-
ians and could not be pooled in a meta - analysis. Costa-
los 2003 reported no statistically significant difference in
weight gain (g/week) between the probiotic and control
groups (p>0.05) [median (Interquartile range) of 163.5
(17.7) for the probiotic group (n=51) compared to 155.8
(16.5) for the control group (n=36)] [39]. Stratiki 2007
also reported no statistically significant difference in
weight gain (g/day) between the probiotic and control
groups (p=0.144) [median (range) of 28.3 (12 to 38) for
the probiotic group (n=41) compared to 30 (10 to 40)
for the control group (n=34)] [40].
Linear growth Only one study reported this outcome
but found no statistically significant difference in length
gain (cm/week) between the probiotic and control
groups (p=0.124) [median (range) of 1.4 (0 to 3) for the
probiotic group (n=41) compared to 1.5 (0 to 3.5) for
the control group (n=34)] [40].
Head growth Only one study reported this outcome but
found no statistically significant difference in head
growth (cm/week) between the probiotic and control
groups (p=0.124) [median (range) of 1.1 (0.45 to 1.9) for
the probiotic group (n=41) compared to 0.9 (0 to 2) for
the control group (n=34)] [40].
Secondary outcomes
Complications
Necrotizing enterocolitis [NEC] Two studies (n=162)
reported on NEC and their results were pooled in a
meta-analysis [39,40]. Administration of probiotics failed
to significantly reduce the risk of NEC compared to con-
trols (RR 0.42, 95% CI: 0.15 to 1.16). No significant het-
erogeneity was observed (Chi2=1.06, p=0.30, I2=6%)
(Figure 5).
Sepsis Two studies (n=162) reported on sepsis and their
results were pooled in a meta-analysis [39,40]. Adminis-
tration of probiotics failed to significantly reduce the risk
of sepsis compared to controls (RR 0.40, 95% CI: 0.11 to
1.45. No significant heterogeneity was observed
(Chi2=1.18, p=0.28, I2=15%). (Figure 6)
Figure 5 Effect of probiotic administration on NEC.
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http://www.nutritionj.com/content/11/1/58Other infections No study reported on this outcome.Mortality Only one study [42] reported on mortality.
The risk ratio for this one study (n=30) was calculated
and it showed that the probiotics failed to significantly
reduce the risk of death compared to the control (RR
0.33, 95% CI: 0.04 to 2.85).Number of days on parenteral nutrition No study
reported on this outcome.Number of days to full enteral feed Two studies
reported this outcome but their results could not be
pooled in a meta-analysis because they reported the out-
come in terms of medians and ranges [39,40]. Costalos
2003 reported no statistically significant difference in the
number of days to full enteral feeding between the two
groups (p>0.1) [median (IQR) of 9.3 (2.7) for the pro-
biotic group (n=51) and 9.9 (4.5) for the control group
(n=36)] [32]. Stratiki 2007 also reported no statistically
significant difference in the number of days to full en-
teral feeding [median (range) of 10 (0 to 52) for the pro-
biotic group (n=41) and 10 (0 to 30) for the control
group (n=34)] [40].Maximal enteral feed All four studies reported on this
outcome [39-42]. Results from two studies (n=34) were
pooled in a meta-analysis as they both reported the aver-
age amount of feeding (ml/day) in terms of mean (SD)
[41,42]. There was no statistically significant difference in
the mean amount of feeding (ml/day) between the pro-
biotic and control groups (MD 35.20, 95% CI: -7.61 toFigure 6 Effect of probiotic administration on sepsis.78.02) No statistically significant heterogeneity was
observed between the studies (Chi2=1.65, p=0.20, I2=39%).
Costalos 2003 reported no statistically significant dif-
ference in the milk intake (ml/kg/day) at maximal en-
teral feeding (p>0.1) [median (IQR) of 155 (15) for the
probiotic group (n=51) versus 148 (13) for the control
group (n=36)] [39]. Stratiki 2007 also reported no statis-
tically significant difference in the maximal milk intake
(ml/kg/day) (p=0.624) [median (range) of 210 (165 to
250) for the probiotic (n=41) group versus 192 (120 to
250) for the control group (n=34)] [40].
Feed tolerance: vomiting, gastric aspirate, abdominal
distension Two studies (n=107) reported on vomiting
and were pooled in a meta-analysis [39,42]. There was
no statistically significant difference in the frequency of
vomiting between the probiotic and control groups (RR
0.78, 95% CI: 0.18 to 3.37). No statistically significant
heterogeneity was observed (Chi2=0.41, p=0.52, I2=0%).
In all four probiotic studies, there were no reported
incidences of gastric aspirates, abdominal distension or
diarrhea. Authors were further contacted for clarification
and one responded [42] and stated categorically that
none of these symptoms were observed.
Stool characteristics
Stool frequency Only one study (n=20) reported stool
frequency as the number of episodes of evacuations per
day in terms of mean (SD) [42]. The mean difference for
this one study was calculated and it showed that pro-
biotic consumption resulted in a statistically significant
larger number of stools per day compared to the control
group (MD 1.60, 95% CI: 1.20 to 2.00).
Table 6 Log viable bacteria counts per gram of stool in
positive infants fed probiotics
Costalos 2003 [39] Median (IQR)
Pathogens Probiotic Control
n= 51 n=36
Enterococci 2.14 (0.359) 2.19 (0.138)
Bacteriodes 2.17 (0.164) 2.25 (0.363)
Staphylococci 1.23 (0.869) 0.6 (0.281)
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probiotics on stool consistency.
Changes in intestinal permeability Two studies
reported this outcome but their results could not be
pooled in a meta-analysis [39,40]. The studies used two
different tests to test for intestinal permeability. Costalos
2003 used a 1-hour D-Xylose blood test and reported no
statistically significant difference between the two groups
(p>0.1) [median (IQR) of 1.5 (0.4) millimols/L for the
probiotics (n=51) and 1.35 (0.3) mmol/L for the control
(n=36)] [39]. Stratiki 2007 used a lactulose/mannitol
(L/M) urine test and reported no statistically significant
difference in the L/M ratios between the probiotic and
control groups (p=0.073) but the values for median
(range) were presented in a figure from which they
could not be accurately extracted [40].
Changes in gastrointestinal micro flora
Bifidobacteria Two studies reported on bifidobacteria
but their results could not be pooled in a meta-analysis
[39,40]. Costalos 2003 reported a significantly higher log
viable Bifidobacteria counts per gram of positive infants in
the probiotics group compared to the controls (p<0.001)
[median (IQR) of 2.65 (0.083) for the probiotics group
(n=51) and 2.27 (0.075) for the control group (n=36)] [39].
Stratiki 2007 reported bifidobacteria in terms of log 10
cfu/g wet feces but found no statistically significant differ-
ence between the two groups (p=0.075) [median (range)
of 9.7 (7.5-10.3) for the probiotics group (n=41) and 8.9
(7.2-10.2) for the control group (n=34)] [40].
Lactobacillus Only one study reported on lactobacillus
[39]. This study reported no statistically significant dif-
ference in the log viable bacterial lactobacillus counts
per gram of positive infants between the two groups
(p>0.05) [median (IQR) of 1.57 (0.285) for the probiotics
group (n=51) and 1.42 (0.287) for the control group
(n=36)].
Pathogens Only one study reported this outcome (en-
terococci, bacteroides, and staphylococci) in terms of the
median (IQR) of log viable bacterial counts per gram of
positive infants [39] (Table 6). The study reported sig-
nificantly higher counts of Enterococci (p<0.05) and
Staphylococci (p<0.001) in the probiotic group com-
pared to the controls. However, the study found no sta-
tistically significant difference in the counts of
bacteroides between the two groups (p>0.05).
Prebiotic versus control
Four studies investigated the effect of prebiotics admin-
istration versus no prebiotics (control group) [36,43-45].Primary outcomes: short-term growth parameters
Weight gain All four studies reported on weight gain
[36,43-45]. Results from three studies (n=106) were
pooled in a meta-analysis [36,43,45]. Moderate hetero-
geneity was observed between the studies (Chi2=4.04,
p=0.13, I2=51%). An investigation of heterogeneity by
subgroup analysis with respect to the prebiotic type used
(GOS/ FOS versus FOS only) yielded statistically signifi-
cant subgroup differences (Chi2=4.04, df=1, p=0.04,
I2=75.2%) implying that prebiotic type may be the source
of heterogeneity. There was no statistically significant
heterogeneity between the two studies in the GOS/ FOS
subgroup (Chi2=0.01, df=1, p=0.94, I2=0%) [36,43]. The
results for the GOS/FOS subgroup yielded no significant
difference in weight gain (g/ day) between the two
groups (MD 0.04, 95% CI: -2.65 to 2.73, n=50, 2 studies)
while the other FOS subgroup yielded a significantly
higher weight gain in controls compared to the prebio-
tics (MD −4.60, 95% CI: -8.24 to −0.96, n=56, 1 study).
(Figure 7) Sensitivity analysis with respect to study qual-
ity could not be done because all three studies were of
poor quality since the methods used for sequence gener-
ation, allocation concealment and blinding were all not
clear.
Mihatsch 2006 reported no statistically significant dif-
ference in weight gain (g/kg/day) between the two
groups (p=0.4) [median (range) of 17.6 (8.1 to 23.4) for
the prebiotic group (n=10) compared to 13 (9.3 to 21.9)
for the control group (n=10)] [44].
Linear growth Three studies reported on length gain
[36,43,45]. Meta-analysis of the results from these three
studies (n=106) revealed significant heterogeneity be-
tween the three studies (Chi2 = 139.41, df = 2, p <
0.00001, I2 = 99%). An investigation of heterogeneity by
subgroup analysis with respect to the prebiotic type
used (GOS/ FOS versus FOS only) yielded statistically
significant subgroup differences (Chi2=139.41, df=1,
p<0.00001, I2=0%) implying that prebiotic type may be
the source of heterogeneity. There was no statistically
significant heterogeneity between the two studies in the
GOS/ FOS subgroup (Chi2=0.17, df=1, p=0.68, I2=0%).
[36,43]. The results for the GOS/FOS subgroup yielded
Figure 7 Effect of prebiotic administration of weight gain (g/day).
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week) between the two groups (MD 0.01, 95% CI: -0.03
to 0.04, n=50, 2 studies) while the other FOS subgroup
yielded a significantly higher length gain (cm/ week) in
prebiotics compared to the controls (MD 0.30, 95% CI:
0.27 to 0.33, n=56, 1 study). (Figure 8) Sensitivity ana-
lysis with respect to study quality could not be done
because all three studies were of poor quality since the
methods used for sequence generation, allocation con-
cealment and blinding were all not clear.Head growth Two studies reported on head growth
(cm/week) [43,45]. Meta-analysis of the results from
these two studies (n=76) failed to yield statistically sig-
nificant difference in head growth (MD −0.01, 95% CI:
-0.02 to 0.00). No significant heterogeneity was detected
between the two studies (Chi2 = 0.10, p =0.75, I2 = 0%).Secondary outcomes
Complications No prebiotic study reported on Necro-
tizing Enterocolitis (NEC), Sepsis, other infections and
mortality.Figure 8 Effect of prebiotic administration of linear growth (cm/weekFeeding tolerance
Number of days on parenteral nutrition No study
reported on parenteral nutrition.
Age at full enteral feed Two studies reported on age at
full enteral feeds [36,45]. Meta-analysis of the results
from these two studies (n=86) did not find statistically
significant difference in the age at full enteral feed (MD
−0.79, 95% CI: -2.20 to 0.61). No significant heterogen-
eity was detected between the two studies (Chi2 =1.16,
p =0.28, I2 = 14%).
Maximal enteral feed Two studies reported on this
outcome but their results could not be pooled in a
meta-analysis [36,44]. Boehm 2002 reported the feeding
volume (ml/kg/day) in terms of the mean (SD) and
therefore a mean difference was calculated. There was
no statistically significant difference in feeding volume
between the prebiotics group (n=15) and control groups
(n=15) (MD −4.10, 95% CI: -18.16 to 9.96) [36].
Mihatsch 2006 reported no statistically significant dif-
ference in the average formula intake within the study
period (ml/kg/d) between the two groups (p=0.35) [me-
dian (range) of 156 (127 to 165) for the prebiotic group).
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http://www.nutritionj.com/content/11/1/58(n=10) compared to 151 (117 to 169) for the control
group (n=10)] [44].
Feed tolerance: vomiting, gastric aspirate, abdominal
distension, diarrhea All four studies reported this out-
come [36,43-45]. In all 4 studies (n=126), there were no
observed incidences of feed intolerance. There was no
vomiting, gastric aspirate removed, no abdominal disten-
sion or diarrhea reported. All infants tolerated the pre-
term formula with prebiotic or control. From further
communication with study authors, 2 study authors
[43,44] responded that none of these outcomes were
observed.
Stool characteristics
Stool frequency Three studies reported on stool fre-
quency [36,44,45]. Two studies reported the results in
form of mean (SD) of the number of stools per day
(number/ day) [36,45]. Meta-analysis of results from
these two studies (n=86) showed a significantly higher
stool frequency in the prebiotic group compared to the
control group (MD 0.80, 95% CI: 0.48 to 1.1). No signifi-
cant heterogeneity was detected between the two studies
(Chi2 =0.13, p =0.72, I2 = 0%) (Figure 9).
Mihatsch 2006 reported no statistically significant dif-
ference in stool frequency between the two groups
(p=0.059) [median (range) of 3.6(1.7 to 6.9) stools/day in
prebiotic group (n=10) compared to 2.6 (2 to 4.9) stools/
day in control group (n=10)] [44].
Stool consistency Three studies reported on stool
consistency but using three different scales of measurement
[36,44,45]. Although two studies [36,45] both measured
consistency in form of a scale ranging from 1 to 5 and
reported their results as mean (SD), they could not be
pooled in a meta-analysis because their scales were going in
opposite directions; Boehm 2002 (1=watery, 2=soft,
3=seedy, 4=formed, 5=hard) [36]. Kapiki 2007 (5=watery,
4=loose, 3=soft, 2=firm, hard=1) [45]. Themean differences
for these two studies were therefore calculated separately.
In Boehm 2002, the stools from the prebiotic group
(n=15) were significantly more watery as compared to the
control group (n=15). (MD −0.91, 95% CI: -1.41 to −0.37)
[36]. In Kapiki 2007, the stools from the prebiotic groupFigure 9 Effect of prebiotic administration on stool frequency.(n=36) were significantly harder as compared to the control
group (n=20). (MD −0.34, 95% CI: -0.66 to −0.02) [45].
Mihatsch 2006 reported a statistically significantly
lower stool viscosity at day 14 (Newtons) for the prebio-
tics compared to controls (p=0.006) [median (range) of
31.8 (1.9 to 67.3) in the prebiotic group (n=10) com-
pared to 157.5 (24.1 to 314.0) in the control group
(n=10)] [44].
Changes in intestinal permeability
No prebiotic study reported on changes in intestinal
permeability.
Changes in gastrointestinal micro flora
Bifidobacteria Two studies reported on this outcome
[36,45]. Meta-analysis of these two studies (n=84)
revealed statistically significant heterogeneity between
the two studies (Chi2 =7.63, p =0.006, I2 = 87%). An in-
vestigation of heterogeneity by subgroup analysis with
respect to the prebiotic type used (GOS/ FOS versus
FOS only) yielded statistically significant subgroup dif-
ferences (Chi2 =7.63, p =0.006, I2 = 86.7%) implying that
prebiotic type may be the source of heterogeneity. The
results for the GOS/FOS subgroup yielded significantly
higher bifidobacteria counts in prebiotics compared to
controls (MD 2.10, 95% CI: 0.96 to 3.24) [36]. The other
FOS subgroup also yielded significantly higher bifidobac-
teria counts in prebiotics compared to controls (MD
0.48, 95% CI: 0.28 to 0.68) [45] (Figure 10).
Lactobacilli Only one study [36] reported this outcome
but the actual values were not given.
Pathogens [Post-intervention] Two studies reported
on this but their results could not be pooled in a meta-
analysis [36,45]. Boehm 2002 reported the sum of clinic-
ally relevant pathogens at the end of the intervention
period in the form of mean (SD) log cfu/g stool. The
values were used to calculate the mean difference which
showed that the sum of the studied pathogens was sig-
nificantly lower in the prebiotic group (n=12) compared
to the control group (n=13). (MD −0.43, 95% CI: -0.79
to −0.07) [36].
Figure 10 Effect of prebiotic administration on total counts of Bifidobacteria.
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coli, bacteroides, and enterococci) in terms of mean
(SD) log 10 CFU/g wet feces [45]. Mean differences for
each of these pathogens were calculated. There was no
statistically significant difference in the number of
staphylococci (MD 0.00, 95% CI: -0.17 to 0.17) between
the two groups but there were significantly fewer E. coli
(MD −1.69, 95% CI: -1.85 to −1.53) and enterococci
(MD −0.80, 95% CI: -0.99 to −0.61) in the prebiotic
group (n=36) compared to the control group (n=20).
With regards to bacteroides, there were significantly
more bacteroides in the prebiotic group (n=36) com-
pared to the control group (n=20) (MD 0.50, 95% CI:
0.36 to 0.64) [45].
Discussion
The objective of this review was to assess if addition of
probiotics or prebiotics to preterm infant formula led to
improved growth and clinical outcomes in preterm or
low birth weight infants. Studies that used breast milk or
mixed feeds (breast milk and infant formula) were
excluded. All RCTs evaluated probiotics or prebiotic use
in preterm infants, were of small sample size, varied in
enrolment criteria, intervention, treatment initiation and
duration.
Summary of main findings
Probiotics
This review was under powered to detect clinically
important differences in primary outcomes (weight
gain, linear growth, head growth) because of the few
number of studies, small sample size (n=34) and poor
methodological quality of studies. This review found
no significant effect on weight gain from use of pro-
biotics added to infant formula. There was also no
significant probiotic effect on linear and head growth
from the one study measuring these two outcomes.
Probiotic supplementation failed to significantly reduce
the risk of complications such as NEC, sepsis and
death compared to control group. Outcomes such asnumber of days on parenteral nutrition and other
infections were not reported. There was no significant
difference in the amount of feed volume (ml/day) and
frequency of vomiting between study groups. Preterm
infant formula with probiotics was well tolerated as
no gastric aspirates, abdominal distension or diarrhea
was reported. Effects of probiotics on stool character-
istics were under reported. Results from one study
showed probiotics supplementation did result in a lar-
ger number of stools per day.
Effects on intestinal permeability could not be evalu-
ated since two different laboratory tests (lactulose /
mannitol ratio and D- xylose tests) were reported and
the results could not be pooled. Sugar absorption tests
(such as lactulose / mannitol ratio) are a direct measure
of intestine integrity which reflects gut maturation and
in research; they demonstrate the effects of experimental
therapy [78,79]. Monitoring changes in intestinal perme-
ability in preterm infants is essential since there is evi-
dence that initiation of enteral feeds decreases intestinal
permeability [78,80]. However, this could not be estab-
lished in this review. Other outcomes such as age at full
enteral feeds and intestinal micro flora (pathogens)
could not be evaluated as medians (inter quartile ranges)
were reported. No probiotic study reported any data on
low birth weight infants therefore no conclusions could
be made on this population.
The included probiotic studies had short treatment
duration of 30 days. This confirms the European Society
for Pediatric, Gastroenterology, Hepatology and Nutri-
tion (ESPGHAN) statement that there is a “lack of pub-
lished evidence on clinical benefits from long term use
of probiotic containing infant formula” [81]. This review
confirms that there is a need for long term follow-up
RCTs on preterm infants. Live probiotic bacteria were
used in the trials. There have been few reports of bacter-
aemia from probiotic use in the biomedical literature
[82-84]. There were no cases of sepsis reported as a re-
sult of probiotic consumption in the included studies. In
recent reviews, the time to reach full enteral feeds was
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breast milk or mixed feeds. This review could not evalu-
ate this outcome. Well-designed RCTs with similar feed-
ing regimes are needed to evaluate this outcome.
Prebiotics
This review was under powered to detect clinically im-
portant differences in primary outcomes (weight gain,
linear growth, head growth) because of few number of
studies, small sample size (n=106) and poor methodo-
logical quality of studies. Addition of prebiotic combina-
tions of GOS /FOS or FOS alone to preterm infant
formula did not have any significant effect on weight
gain. Addition of GOS / FOS to preterm infant formula
did not have any effect on linear growth. However,
addition of FOS alone did have a significant effect on
linear growth. Neither GOS / FOS combination nor FOS
alone had any effect on head growth.
None of the prebiotic studies reported on NEC, sepsis,
other infections, mortality (death), parenteral nutrition
or changes in intestinal permeability; therefore these
outcomes could not be evaluated. Prebiotics did not
have any significant effect on the age at which infants
reached full enteral feeds or volume of feed tolerated.
Prebiotic preterm formula was well tolerated because
there were no reports of vomiting, gastric aspirates, ab-
dominal distension or diarrhea. Prebiotic supplementa-
tion did result in a higher stooling frequency compared
to control. Effects on stool consistency were inconclusive
as results from one study resulted in more watery stools
in the prebiotic study group compared to control group,
in a second study, the prebiotic group experienced
harder stools compared to control group. The third
study results were presented in medians (range) there-
fore no conclusions could be made. In preterm infants,
frequent watery stools may signify intolerance, a transi-
ent lactase deficiency or another pathological state which
always require further investigation [6].
Prebiotics did have a significant effect on intestinal
micro flora. Addition of GOS / FOS combination or
FOS alone significantly increased counts of bifidobac-
teria. Effects on lactobacillus counts could not be evalu-
ated as actual figures were not available. The sum of
studied pathogens and some selected pathogens (E- coli,
enterococci) were significantly fewer in the prebiotic
group compared to control group. There was no effect
on staphylococci levels while bacteroides were signifi-
cantly higher in the probiotic group compared to control
group. No prebiotic study reported any data on low birth
weight infants; therefore no evaluations could be made.
The prebiotic studies were of short duration ranging
from 14 to 28 days. The dose of the prebiotic used
(GOS, FOS) varied from 0.4 g/dl o 1g/dl. The European
Committee on Food recommends that prebiotics addedto formula milk do not exceed 0.8 g/100 ml. The ration-
ale for prebiotic doses not exceeding 1g/ml in clinical
trials is an attempt to maximize the bifidogenic effect
with minimal intolerance as exhibited by, abdominal dis-
tension [85]. The preterm infants tolerated the prebiotic
formula as there were no symptoms of feed intolerance
reported.
Prebiotic supplementation did have some short term
benefits: increased stooling frequency and bifidobacteria
counts, fewer pathogens in the prebiotic group com-
pared to control group. However, large RCTS with long
term follow -up are needed to find out if these short
term benefits translate into improved general health
and reduced morbidities in preterm infants. Due to the
short duration of prebiotic studies, routine supplemen-
tation with prebiotics in preterm infants cannot be
recommended.
Quality of the evidence and potential biases
In this review, the quality of the evidence was compro-
mised by several factors: Sample size: included studies
were of small individual sample size, number of study
participants ranged from 20 to 87 in the probiotic stud-
ies, 20 to 56 in prebiotic studies. Intervention: Different
types of probiotic and prebiotics, doses and treatment
duration were used. Methodological quality: Inadequate
information was published to assess methodological
quality of the studies. Information was missing on se-
quence generation, allocation concealment, blinding, in-
complete outcome data, selective reporting and free of
other bias domains. The significance of any relationship
between methodological quality and study outcomes
could not be verified since no subgroup analysis with re-
spect to study quality could be done as a result of either
too few studies in a meta-analysis or having all studies
with similar quality in a meta-analysis. Not all the
reviews pre- specified outcomes were addressed by the
included studies.
At the conclusion of the review process and prepar-
ation of the manuscript (for this review), one on- going
study was terminated due to being under powered [47].
One study was completed and data analysis commenced.
The results from this study could not be included in this
review [48]. The other three studies were still on-going
[46,49,50]. The reviewers used thorough comprehensive
search strategies adopted for the available databases. All
attempts were made to minimize publication bias. All
steps of this review were conducted independently by
the reviewers.
Agreements and disagreements with other reviews
No significant difference was found in contrast with past
reviews and that the potential reasons are lack of power,
poor quality of studies or a lack of effect in formula fed
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reviews. Prebiotics did have an impact on GI micro flora
(increased bifidobacteria counts, reduction in certain
pathogens); feed tolerance (no reported gastric aspirates,
abdominal distension).
Conclusion
There is not enough evidence to state that supplementa-
tion of preterm infant formula with probiotics or prebio-
tics does result in improved growth and clinical
outcomes in preterm infants. Therefore this review does
not support the routine supplementation of preterm for-
mula with probiotics or prebiotics.
Implications for research
For clear recommendations to be made, long term large
RCTs on exclusively formula fed preterm and low birth
weight infants are required to investigate the effects of
probiotics and prebiotics supplementation in preventing
NEC, sepsis, death/mortality; changes in intestinal micro
flora and intestinal permeability; explore the efficacy of
different doses of the same probiotic on clinical out-
comes because available studies used different probiotic
doses; similarly, explore the efficacy of different doses of
the same prebiotic on clinical outcomes because avail-
able studies used similar prebiotics with different doses
and treatment duration.
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